Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | USP8 | P40818 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | GAPDH | P04406 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822188 | 0.78 | ALDH1A1 (0.54) | CA1CA2CA7CA9LCK | |
| SCHEMBL8993580 | 0.78 | XIAP (0.39) | CYP3A4XIAP | |
| SCHEMBL30002673 | 0.78 | XIAP (0.39) | CYP3A4XIAP | |
| SCHEMBL10494191 | 0.78 | EPHX2 (0.56) | EPHX2CYP3A4ACHEHTT | |
| SCHEMBL9178309 | 0.77 | BCL2 (0.48) | P4HBCYP3A4XIAP | |
| SCHEMBL5810336 | 0.77 | CA1 (0.54) | CA1CA2CA7CA9LCK | |
| SCHEMBL4294055 | 0.77 | PTPN1 (0.53) | CA1CA2CA7CA9LCK | |
| SCHEMBL9178172 | 0.77 | PTPN1 (0.49) | CA1CA2CA7CA9LCK | |
| SCHEMBL30003052 | 0.77 | PTPN1 (0.49) | CA1CA2CA7CA9LCK | |
| SCHEMBL29406983 | 0.77 | PTPN1 (0.53) | CA1CA2CA7CA9LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829427-B2 | Naphthoquinones, pro-drugs, and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829427-B2 | Naphthoquinones, pro-drugs, and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190071380-A1 | NAPHTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071380-A1 | NAPHTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2017106624-A1 | NAPTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106624-A1 | NAPTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-2532390-B1 | Pharmaceutical composition for liver diseases. | MD BIOALPHA CO LTD (KR) | 2016-08-17 | — | — | EP | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| WO-2013159224-A1 | 2-CARBAMO(THIO)YL-1,3- DIOXOPROPYL DERIVATIVES IN CANCER THERAPY | UNIVERSITY OF MANITOBA (CA) | 2013-10-31 | — | — | WO | disclosed |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | KT & G CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| US-20100239674-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | KT & G CO., LTD. (KR) | 2010-09-23 | — | — | US | disclosed |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MD BIOALPHA CO., LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
| EP-2099449-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | Mazence Inc. (KR) | 2009-09-16 | — | — | EP | disclosed |
| EP-2099448-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | Mazence Inc. (KR) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009082124-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA | MAZENCE INC. (KR) | 2009-07-02 | — | — | WO | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008066297-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066299-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| EP-1848432-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | Md Bioalpha Co., Ltd. (KR) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006088315-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MD BIOALPHA CO., LTD. (KR) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829427-B2 | Naphthoquinones, pro-drugs, and methods of use thereof | NQO1, RECQL, ABCB1 | CA1 4697/4885CA2 4710/4885CA7 3448/4885 |
| US-20190071380-A1 | NAPHTHOQUINONES, PRO-DRUGS, AND METHODS OF USE THEREOF | NQO1, RECQL, ABCB1 | CA1 4697/4885CA2 4710/4885CA7 3448/4885 |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | SLC25A20, SLC25A1, PC | CA1 4463/4885CA2 2776/4885CA7 3101/4885 |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | NDUFAB1, CS, NLN | CA1 4514/4885CA2 2707/4885CA7 3366/4885 |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | NLN, SLC25A20, ACAD9 | CA1 4643/4885CA2 3707/4885CA7 3956/4885 |
| US-20100239674-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | PDE3A, PDE3B, PDE2A | CA1 4773/4885CA2 4107/4885CA7 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.